Biosenta Inc. Announces Private Placement of up to 7,500,000 Units at $0.15 per Unit and Grant of Stock Options

BIOSENTA INC. (CNSX:ZRO) (the "Company") is pleased to announce a private
placement of up to 7,500,000 units at a price of $0.15 per unit for gross
proceeds of up to $1,125,000 (the "Offering"). Each unit consists of one Class A
Share and one-half of one Class A Share purchase warrant. Each whole warrant
will entitle the holder to purchase one additional Class A Share in the capital
of the Corporation (a "Warrant Share") at an exercise price of $0.20 per Warrant
Share to the extent such Warrant is exercised on or before the date that is 18
months from the closing date of the Offering. All securities issued will be
subject to a four-month hold period. The proceeds will be used for working
capital purposes and in furtherance of the Company's activities in connection
with development of product lines, including development of its pilot plant and
research facility Parry Sound, Ontario.


The Company also announces that it has granted a total of 950,000 stock options
to purchase Class A Shares of the Company to employees of the Company. The stock
options have an exercise price of $0.20 per share, they vest one-third
immediately and one-third on each of the first and second anniversaries of the
grant date and they have a term of 5 years. The stock options were granted under
the Company's stock option plan.


About BIOSENTA Inc.

BIOSENTA Inc.'s line of retail anti-microbial products will effectively kill
mold, bacteria and fungi on contact and prevent re-growth. These products
address the demand created by the mounting health and environmental concerns.
Mold can affect the immune system, nervous system, liver, kidneys, blood and
cause brain damage. 


BIOSENTA will also manufacture and distribute an anti-microbial filler. Calcium
Carbonate is one of the most common fillers used industrially. It is susceptible
like other fillers that hold moisture to attracting mold. Annual global revenue
in the calcium carbonate filler industry approximates 140 billion dollars.
BIOSENTA will produce anti-microbial filler that performs 'filling' and
'bulking' functions like calcium carbonate. BIOSENTA's filler product will not
attract moisture and consequently mold infestation. BIOSENTA's filler with its
anti-microbial high ph core in individual particles will enhance commercial
product life and eradicate a broad spectrum of known bacteria, fungi, algae and
other micro-organisms by suppression of their reproduction.


On behalf of the Board of Directors of BIOSENTA Inc. 

Bruce Lewis, CEO & President

The CNSX has in no way passed upon the merits of the proposed transaction and
has neither approved nor disapproved of the contents of this press release.
Neither the CNSX nor its Regulation Services Provider (as such term is defined
in the policies of the CNSX) accepts responsibility for the adequacy or accuracy
of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
BIOSENTA Inc.
Bruce Lewis
CEO & President
416-410-2019


Investor Cubed Inc.
Neil Simon
Investor Relations Contact
647-258-3311 or 888-258-3323
[e-mail]